Sanders and Cassidy lay out health committee agenda; venture capital invests little in addiction treatments

Taking stock of the drug industry, from the lab to the medicine chest

February 2, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Chip Somodevilla/Getty Images STAT+ | From industry 'greed' to workforce shortages, Sanders and Cassidy lay out health committee agenda STAT separately spoke with both senators about where they think Democrats and Republicans can work together on the health care agenda. By Sarah Owermohle Venture capital is investing little in new treatment for addiction, report finds Investment firms have poured roughly 270 times more money into developing cancer drugs than addiction cures, the trade group BIO reports. By Lev Facher Listen: Pharma blockbusters, pandemic policy, & legal chicanery STAT's Rachel Cohrs joins us to explain the looming end of Covid-19's status as a federal emergency and the public health implications. By Damian Garde and Meg Tirrell and Adam Feuerstein Adobe Opinion: Generics: a missing piece in China's Covid-19 crisis response By not allowing the importation of foreign-made generics, China is making it difficult for its citizens to get access to Paxlovid. By Cathy Tie These blood-clot catching devices have been controversial for years. Why are doctors still relying on them? Inferior vena cava filters are supposed to save lives by preventing embolisms. But the devices can cause serious problems for patients. By Lizzy Lawrence

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

REPORTS NEWSLETTERS EVENTS STAT+

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser